Bart A. Nijmeijer
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Preclinical targeting of liver fibrosis with a 89Zr-labeled Fibrobody® directed against platelet derived growth factor receptor-β.
Journal: European journal of nuclear medicine and molecular imaging
Published: April 17, 2024
Combined inhibition of bile salt synthesis and intestinal uptake reduces cholestatic liver damage and colonic bile salts in mice.
Journal: JHEP reports : innovation in hepatology
Published: April 03, 2023
Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis.
Journal: Hepatology (Baltimore, Md.)
Published: February 02, 2022
The non-selective Rho-kinase inhibitors Y-27632 and Y-33075 decrease contraction but increase migration in murine and human hepatic stellate cells.
Journal: PloS one
Published: January 22, 2022
An Efficient Conjugation Approach for Coupling Drugs to Native Antibodies via the PtII Linker Lx for Improved Manufacturability of Antibody-Drug Conjugates.
Journal: Angewandte Chemie (International ed. in English)
Published: August 24, 2020
First platinum(II)-based metal-organic linker technology (Lx®) for a plug-and-play development of antibody-drug conjugates (ADCs).
Journal: Expert opinion on drug delivery
Published: July 23, 2019
Enhanced Factor IX Activity following Administration of AAV5-R338L "Padua" Factor IX versus AAV5 WT Human Factor IX in NHPs.
Journal: Molecular therapy. Methods & clinical development
Published: May 17, 2019
Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs.
Journal: Molecular therapy. Methods & clinical development
Published: April 08, 2019
Optimization of viral protein ratios for production of rAAV serotype 5 in the baculovirus system.
Journal: Gene therapy
Published: January 28, 2018
Complement-dependent cytotoxicity induced by therapeutic antibodies in B-cell acute lymphoblastic leukemia is dictated by target antigen expression levels and augmented by loss of membrane-bound complement inhibitors.
Journal: Leukemia & lymphoma
Published: February 01, 2017
Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.
Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Published: October 09, 2012
Showing 1-12 of 12
Last Updated: 09/26/2026